PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery
Authors
Keywords
-
Journal
DRUG DISCOVERY TODAY
Volume 28, Issue 1, Pages 103395
Publisher
Elsevier BV
Online
2022-10-11
DOI
10.1016/j.drudis.2022.103395
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rational Design for Nitroreductase (NTR)-Responsive Proteolysis Targeting Chimeras (PROTACs) Selectively Targeting Tumor Tissues
- (2022) Shi Shi et al. JOURNAL OF MEDICINAL CHEMISTRY
- PROTAC targeted protein degraders: the past is prologue
- (2022) Miklós Békés et al. NATURE REVIEWS DRUG DISCOVERY
- PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery
- (2021) Giuseppe Ermondi et al. MOLECULES
- Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery
- (2021) Guoqiang Dong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras
- (2021) Troy A. Bemis et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design, Synthesis, and Evaluation of Trivalent PROTACs Having a Functionalization Site with Controlled Orientation
- (2021) Yifan Huang et al. BIOCONJUGATE CHEMISTRY
- Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity
- (2021) Satomi Imaide et al. Nature Chemical Biology
- Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
- (2021) Dongwen Lv et al. Nature Communications
- New therapeutic modalities in drug discovery and development: Insights & opportunities
- (2021) Manfred Kansy et al. ADMET and DMPK
- Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
- (2020) Jay B. Fell et al. JOURNAL OF MEDICINAL CHEMISTRY
- The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
- (2020) Mikołaj Słabicki et al. NATURE
- The Missing Link between (Un)druggable and Degradable KRAS
- (2020) Elena De Vita et al. ACS Central Science
- Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
- (2020) Michael J. Bond et al. ACS Central Science
- Developing drugs for the ‘undruggable’
- (2020) Abigail Sawyer BIOTECHNIQUES
- Cryo-Electron Microscopy Reaches Resolution Milestone
- (2020) Mark Peplow ACS Central Science
- Small-molecule-induced polymerization triggers degradation of BCL6
- (2020) Mikołaj Słabicki et al. NATURE
- Solution Conformations Shed Light on PROTAC Cell Permeability
- (2020) Yoseph Atilaw et al. ACS Medicinal Chemistry Letters
- The PROTAC technology in drug development
- (2019) Yutian Zou et al. CELL BIOCHEMISTRY AND FUNCTION
- Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction
- (2019) Kyle R. Simonetta et al. Nature Communications
- In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application
- (2019) Michael L. Drummond et al. Journal of Chemical Information and Modeling
- Drug Design of “Undruggable” Targets
- (2019) Jie Wang et al. CHINESE JOURNAL OF CHEMISTRY
- Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges
- (2019) Scott D. Edmondson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Targeted protein degradation: elements of PROTAC design
- (2019) Stacey-Lynn Paiva et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
- (2019) William Farnaby et al. Nature Chemical Biology
- PROTACs– a game-changing technology
- (2019) Markella Konstantinidou et al. Expert Opinion on Drug Discovery
- Development of targeted protein degradation therapeutics
- (2019) Philip P. Chamberlain et al. Nature Chemical Biology
- PROTACs as Potential Therapeutic Agents for Cancer Drug Resistance
- (2019) Xiuyun Sun et al. BIOCHEMISTRY
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds
- (2019) Zhaoyang Li et al. NATURE
- Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
- (2019) Tyler B. Faust et al. Nature Chemical Biology
- Targeted protein degradation: expanding the toolbox
- (2019) Matthieu Schapira et al. NATURE REVIEWS DRUG DISCOVERY
- Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820
- (2019) Xinlin Du et al. STRUCTURE
- Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- Molecular glue concept solidifies
- (2019) Kheewoong Baek et al. Nature Chemical Biology
- Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex
- (2019) Dirksen E. Bussiere et al. Nature Chemical Biology
- A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
- (2019) Sajid Khan et al. NATURE MEDICINE
- Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space
- (2018) Vasanthanathan Poongavanam et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway
- (2018) Mengchen Lu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Impact of Dynamically Exposed Polarity on Permeability and Solubility of Chameleonic Drugs Beyond the Rule of 5
- (2018) Matteo Rossi Sebastiano et al. JOURNAL OF MEDICINAL CHEMISTRY
- Plasticity in binding confers selectivity in ligand-induced protein degradation
- (2018) Radosław P. Nowak et al. Nature Chemical Biology
- Pharmacological targeting of RAS: Recent success with direct inhibitors
- (2018) John P. O’Bryan PHARMACOLOGICAL RESEARCH
- Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
- (2017) Kwok-Ho Chan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- VoroMQA: Assessment of protein structure quality using interatomic contact areas
- (2017) Kliment Olechnovič et al. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
- The Ubiquitin Code in the Ubiquitin-Proteasome System and Autophagy
- (2017) Yong Tae Kwon et al. TRENDS IN BIOCHEMICAL SCIENCES
- FRODOCK 2.0: fast protein–protein docking server
- (2016) Erney Ramírez-Aportela et al. BIOINFORMATICS
- Targeting Cullin–RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation
- (2015) Emil Bulatov et al. BIOCHEMICAL JOURNAL
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
- (2014) Eric S. Fischer et al. NATURE
- A Comprehensive Mathematical Model for Three-Body Binding Equilibria
- (2013) Eugene F. Douglass et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Impact of linker length on the activity of PROTACs
- (2010) Kedra Cyrus et al. Molecular BioSystems
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- FRODOCK: a new approach for fast rotational protein–protein docking
- (2009) José Ignacio Garzon et al. BIOINFORMATICS
- The 26 S Proteasome: From Basic Mechanisms to Drug Targeting
- (2009) Ami Navon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The RosettaDock server for local protein-protein docking
- (2008) S. Lyskov et al. NUCLEIC ACIDS RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started